Journal of Tissue Viability
Volume 19, Issue 3 , Pages 116-122, August 2010

Tolerability and safety of conventional therapy combination with DeMarco formula for infected ischemic diabetic foot

  • Héctor Álvarez Duarte

      Affiliations

    • National Institute for Angiology and Vascular Surgery, Research Department, 1551 Calzada del Cerro, Postal code 12000, Havana City, Cuba
  • ,
  • Martha M. Fors López

      Affiliations

    • National Center for the Coordination of Clinical Assays, Havana, Cuba
  • ,
  • José Hernández Carretero

      Affiliations

    • National Institute for Angiology and Vascular Surgery, Research Department, 1551 Calzada del Cerro, Postal code 12000, Havana City, Cuba
  • ,
  • Miriam Mahia Vilas

      Affiliations

    • National Institute for Angiology and Vascular Surgery, Research Department, 1551 Calzada del Cerro, Postal code 12000, Havana City, Cuba
  • ,
  • Milagros García Mesa

      Affiliations

    • National Institute for Angiology and Vascular Surgery, Research Department, 1551 Calzada del Cerro, Postal code 12000, Havana City, Cuba
    • Corresponding Author InformationCorresponding author. Tel.: +537 878 6102.

published online 07 June 2010.

Abstract 

Background

A study has found that major amputations are necessary on 69% of ischemic diabetic foot patients treated with conventional therapy. An uncontrolled study of 31 patients showed that only 33% needed major amputation after treatment with conventional therapy plus De Marco Formula (DMF), a novel formulation of procaine and Polyvinylpyrrolidone.

Objective

To assess the tolerability and safety of the combination of conventional therapy and De Marco Formula for infected ischemic diabetic foot.

Methods

Adult patients, 10 male/24 female, were treated with the conventional therapy for diabetic foot plus DMF (0.15ml/kg/day IM) during ten days and then twice a week until healing of the lesions or completion of a 52-day period. Required amputations, lesion areas, adverse events occurrence and clinical laboratory parameters (hemoglobin, blood cell counts, glycosilated hemoglobin, total proteins, creatinine, alanine transaminase and alkaline phosphatase) were determined during the treatment period.

Results

Two slight (5.88%) and one moderate (2.94%) adverse events (mainly cutaneous rash) were reported. The last one was reported on the 15th day of treatment and DMF dosing was discontinued by patient’s request. Clinical laboratory mean values remained within normal ranges during treatment except for blood leukocyte counts that pathologically elevated at baseline and decreased to normality by treatment end. This study has found that 18.08% of patients (N=6) needed a lower limb amputation with the combined treatments. The standard reported rate in Cuba is 25–29%. Furthermore, a progressive reduction of the mean lesion area from 51.29cm2 at the beginning to 1.89cm2 at the end of the treatment (p=0.000001) was observed.

Conclusion

The treatment with De Marco Formula for 52 days as an adjuvant for the conventional therapy for infected ischemic diabetic foot was well tolerated and safe. These findings are consistent with those of a randomized prospective controlled study performed later.

Keywords: Diabetic foot, Lower limb amputation, Procaine, De Marco formula

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0965-206X(10)00035-5

doi:10.1016/j.jtv.2010.03.002

Journal of Tissue Viability
Volume 19, Issue 3 , Pages 116-122, August 2010